Alvotech is a privately owned, fully integrated specialty biopharmaceutical company focused exclusively on development and manufacturing of high quality biosimilar products. We are specialists in biogeneric product creation, all along the value chain from cell line development to commercial manufacturing. Our common goal: to be a global leader in the biosimilar space and to deliver high quality cost competitive products to patients worldwide.
We come from all around the world, bringing literally thousands of years of combined knowledge and expertise to our mission.
Our vision as a company is to build a leading global biopharmaceutical company, while focusing on the development, and the commercialization of medicines for the treatment of severe, immune, inflammatory conditions.
Our biosimilar assets include six biosimilar monoclonal antibodies that are developed in our four research & development centers located across Europe and will be manufactured in our state-of-the-art facility located in Reykjavik Iceland.
We develop, produce and release our biosimilars in house with the latest available technology and to the highest quality standards for the supply of finished and ready to commercialize products to our partners worldwide
Alvogen’s leadership team is dedicated to fostering a dynamic change-driven culture committed to meeting the needs of our customers. Our organizational structure is lean and flexible, driving quick and effective decision making and thus enabling the company to bring new generic products quickly and safely to market.